Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease

Cancer Immunology, Immunotherapy

Volumn 64, Issue 3, 2015, Pages 287-297

  Shams, Madeeha ^a   Owczarczak, Barbara ^a   Manderscheid Kern, Patricia ^a   Bellnier, David A ^a   Gollnick, Sandra O ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Anti tumor immunity; Cancer; Combination therapy; Photodynamic therapy

Indexed keywords

CASPASE 3; PHOTOFRIN; PHOTOSENSITIZING AGENT; PYROGEN FREE 2 [1 HEXYLOXYETHYL] 2 DEVINYL PYROPHEOPHORBIDE A; UNCLASSIFIED DRUG; 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A; ANTINEOPLASTIC AGENT; CHLOROPHYLL; PHOTOFRIN II;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CELL ACTIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; INFLAMMATION; MOUSE; NEUTROPHIL; NONHUMAN; PHOTODYNAMIC THERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; COLONIC NEOPLASMS; GENETIC TRANSFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; METASTASIS; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; RANDOMIZATION; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHLOROPHYLL; COLONIC NEOPLASMS; DIHEMATOPORPHYRIN ETHER; FEMALE; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RANDOM ALLOCATION; T-LYMPHOCYTES; TRANSFECTION;

EID: 84925521858     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1633-9     Document Type: Article

References (43)

1. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J (2011) Photodynamic therapy of cancer: an update. CA Cancer J Clin 61:250–281
2. Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, Morgan J (2004) Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 64:2120–2126
3. Brackett CM, Gollnick SO (2011) Photodynamic therapy enhancement of anti-tumor immunity. Photochem Photobiol Sci 10:649–652
4. Mroz P, Hashmi JT, Huang YY, Lange N, Hamblin MR (2011) Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol 7:75–91
5. Kousis PC, Henderson BW, Maier PG, Gollnick SO (2007) Photodynamic therapy (PDT) enhancement of anti-tumor immunity is regulated by neutrophils. Can Res 67:10501–10510
6. Korbelik M, Krosl G, Krosl J, Dougherty GJ (1996) The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 56:5647–5652
7. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN (2001) Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 61:192–196
8. + T cells and dependent on natural killer cells. Br J Cancer 96:1839–1848
9. Gollnick SO, Evans SE, Baumann H, Owczarczak B, Maier P, Vaughan L, Wang WC, Unger E, Henderson BW (2003) Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 88:1772–1779
10. Firczuk M, Nowis D, Golab J (2011) PDT-induced inflammatory and host responses. Photochem Photobiol Sci 10:653–663
11. Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM (2000) CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med 191:541–550
12. Potter WR (1991) Photodynamic therapy of tumors a review of PDT dosimetry. In: Chester AN, Martellucci S, Scheggi AM (eds) Laser systems for photobiology and photomedicine, vol 252. Springer, Berlin, pp 165–170
13. Henderson BW, Daroqui C, Tracy E, Vaughan LA, Loewen GM, Cooper MT, Baumann H (2007) Cross-linking of signal transducer and activator of transcription 3–a molecular marker for the photodynamic reaction in cells and tumors. Clin Cancer Res 13:3156–3163
14. Gryshuk AL, Chen Y, Potter W, Ohulchansky T, Oseroff A, Pandey RK (2006) In vivo stability and photodynamic efficacy of fluorinated bacteriopurpurinimides derived from bacteriochlorophyll-a. J Med Chem 49:1874–1881
15. Williams MP, Ethirajan M, Ohkubo K, Chen P, Pera P, Morgan J, White WH III, Shibata M, Fukuzumi S, Kadish KM, Pandey RK (2011) Synthesis, photophysical, electrochemical, tumor-imaging, and phototherapeutic properties of purpurinimide-N-substituted cyanine dyes joined with variable lengths of linkers. Bioconjug Chem 22:2283–2295
16. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW (1997) Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 57:3904–3909
17. Barber DL, Wherry EJ, Ahmed R (2003) Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 171:27–31
18. Lethe B, Van den Eynde B, Van Pel A, Corradin G, Boon T (1992) Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 22:2283–2288
19. Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee E (1996) The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93:9730–9735
20. Cerosaletti KM, Blieden TM, Harwell LW, Welsh KM, Frelinger JG, Lord EM (1990) Alteration of the metastatic potential of Line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO of gene transfection. Cell Immunol 127:299–310
21. de Vree WJ, Essers MC, De Bruijn HS, Star WM, Koster JF, Sluiter W (1996) Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res 56:2908–2911
22. Brackett CM, Muhitch JB, Evans SS, Gollnick SO (2013) IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J Immunol 191:4348–4357
23. Hryhorenko EA, Oseroff AR, Morgan J, Rittenhouse-Diakun K (1999) Deletion of alloantigen-activated cells by aminolevulinic acid-based photodynamic therapy. Photochem Photobiol 69:560–565
24. Mroz P, Szokalska A, Wu MX, Hamblin MR (2010) Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One 5:e15194
25. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399–1405
26. Zeitouni NC, Paquette AD, Housel JP, Shi Y, Wilding GE, Foster TH, Henderson BW (2013) A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. Lasers Surg Med 45:89–94
27. Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13:114–119
28. Bianchi ME, Manfredi AA (2009) Immunology. Dangers in and out. Science 323:1683–1684
29. Garg AD, Krysko DV, Vandenabeele P, Agostinis P (2011) DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci 10:670–680
30. Garg AD, Nowis D, Golab J, Agostinis P (2010) Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 15:1050–1071
31. Korbelik M, Zhang W, Merchant S (2011) Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol Immunother 60:1431–1437
32. Panzarini E, Inguscio V, Dini L (2013) Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int. doi:10.1155/2013/482160
33. Tracy EC, Bowman MJ, Henderson BW, Baumann H (2012) Interleukin-1alpha is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts. Br J Cancer 107:1534–1546
34. Garg AD, Krysko DV, Vandenabeele P, Agostinis P (2012) Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 61:215–221
35. Kaech SM, Wherry EJ (2007) Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity 27:393–405
36. Brinkman CC, Peske JD, Engelhard VH (2013) Peripheral tissue homing receptor control of naive, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues. Front Immunol. doi:10.3389/fimmu.2013.00241
37. Masopust D, Schenkel JM (2013) The integration of T cell migration, differentiation and function. Nat Rev Immunol 13:309–320
38. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO (2009) Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res 15:4460–4466
39. Mroz P, Vatansever F, Muchowicz A, Hamblin MR (2013) Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. Cancer Res 73:6462–6470
40. Gomer CJ, Ferrairo A, Murphree AL (1987) The effect of localized porphyrin photodynamic therapy on the induction of tumour metastasis. Br J Cancer 56:27–32
41. Blank M, Lavie G, Mandel M, Keisari Y (2000) Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. Oncol Res 12:409–418
42. Castano AP, Gad R, Zahra T, Hamblin MR (2003) Specific anti-tumor immune response with photodynamic therapy mediated by benzoporphyrin derivative and chlorin(e6). In Jacques SL, Duncan DD, Kirkpatrick SJ Kriete A (eds) Laser-tissue interaction XIV, Proceedings of SPIE, vol 4961. SPIE, WA, pp 1–9
43. Friedberg JS, Culligan MJ, Mick R, Stevenson J, Hahn SM, Sterman D, Punekar S, Glatstein E, Cengel K (2012) Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 93:1658–1665